Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma

Nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for advanced esophageal squamous cell carcinoma

BackgroundNimotuzumab has shown promising efficacy in esophageal squamous cell carcinoma (ESCC). However, the efficacy and safety of nimotuzumab plus chemotherapy and immunotherapy as first-line/neoadjuvant therapy for patients with advanced ESCC remain unclear.MethodsWe performed a real world study...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Wang, Zhi Cui, Muhong Deng, Guoqing Zhang, Fangfang Jing, Yue Ma, Fang Pang, Quanli Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Pharmacology
Subjects:
nimotuzumab
immunotherapy
resectable
unresectable
esophageal squamous cell carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1585048/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items